A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
- 14 March 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 54 (5) , 1080-1088
- https://doi.org/10.1212/wnl.54.5.1080
Abstract
Objective: To evaluate the safety and efficacy of recombinant human nerve growth factor (rhNGF) in HIV-associated sensory neuropathy (SN) within a multicenter, placebo-controlled, randomized trial (ACTG 291). Background: SN affects 30% of individuals with AIDS, is worsened by neurotoxic antiretrovirals, and its treatment is often ineffective. NGF is trophic for small sensory neurons and stimulates the regeneration of damaged nerve fibers. Methods: A total of 270 patients with HIV-associated SN were randomized to receive placebo, 0.1 μg/kg rhNGF, or 0.3 μg/kg rhNGF by double-blinded subcutaneous injection twice weekly for 18 weeks. The primary outcome was change in self-reported neuropathic pain intensity (Gracely Pain Scale). Secondary outcomes included an assessment of global improvement in neuropathy by patients and investigators, neurologic examination, use of prescription analgesics, and quantitative sensory testing. In a subset, epidermal nerve fiber densities were determined in punch skin biopsies. Results: Both doses of NGF produced significant improvements in average and maximum daily pain compared with placebo. Positive treatment effects were also observed for global pain assessments (p = 0.001) and for pin sensitivity (p = 0.019). No treatment differences were found with respect to mood, analgesic use, or epidermal nerve fiber densities. Injection site pain was the most frequent adverse event, and resulted in unblinding in 39% of subjects. Severe transient myalgic pain occurred in eight patients, usually from accidental overdosing. There were no changes in HIV RNA levels or other laboratory indices. Conclusions: We found a positive effect of recombinant human nerve growth factor on neuropathic pain and pin sensitivity in HIV-associated sensory neuropathy. rhNGF was safe and well tolerated, but injection site pain was frequent.Keywords
This publication has 35 references indexed in Scilit:
- Immunohistochemical study of skin reinnervation by regenerative axonsJournal of Comparative Neurology, 1997
- Neurotrophic factors in peripheral neuropathies: Pharmacological strategiesProgress in Neurobiology, 1996
- A standard test of heat-pain responses using CASE IVJournal of the Neurological Sciences, 1996
- The effect of systemically administered recombinant human nerve growth factor in healthy human subjectsAnnals of Neurology, 1994
- Cool, warm, and heat‐pain detection thresholdsNeurology, 1993
- The role of nerve growth factor in collateral reinnervation by cutaneous C-fibres in the ratBrain Research, 1992
- Once-Daily Administration of 2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related ComplexNew England Journal of Medicine, 1990
- Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistryThe Journal of Pathology, 1989
- Evaluation of thermal, pain, and vibration sensation thresholds in newly diagnosed type 1 diabetic patients.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- A Multiple Comparison Procedure for Comparing Several Treatments with a ControlJournal of the American Statistical Association, 1955